To the Editor We have read with great interest the article by Hank et al.1 The authors indicated that neoadjuvant therapy (NAT) could reduce the rate of clinically relevant postoperative pancreatic fistula (CR-POPF). In addition, they demonstrated that CR-POPF is associated with a significant reduction in long-term survival for patients with pancreatic cancer with NAT.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Shi S, Hua J, Yu X. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy. JAMA Surg. 2020;155(3):267–268. doi:10.1001/jamasurg.2019.5089
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.